-

Valneva USA –
Advancing vaccines
for better lives

Valneva is a specialty vaccine company focused on the development, manufacturing and commercialization of prophylactic vaccines for infectious diseases. Our vision is to contribute to a world in which no one dies or suffers from a vaccine-preventable disease.


Valneva USA, Inc. is focused on the marketing and distribution of Valneva’s Japanese encephalitis vaccine, IXIARO®, in the US.

This website is intended for US based healthcare professionals.

PreventJE_Logo.png
Visit PreventJE.com, a website for travel health professionals and their patients, focusing on the risk and prevention of Japanese encephalitis for travelers to Asia.






– Our product

IXIARO®

Japanese encephalitis vaccine
(inactivated, adsorbed)

Read more

How to order IXIARO®
(USA Healthcare Professionals)


US Private Customers:
IXIARO® Authorized Distributors of Record

US Federal Government Customers:
Toll-free number
+1-833-403-8778
Fax
614-495-5555
Email
 
Hours of Operation

Monday to Friday
8:30 a.m. – 5:00 p.m. EST
Medical Inquiries,
Adverse events and
Product complaints
Toll-free number
+1-844-349-4276 


PreventJE_Logo.png
Visit PreventJE.com, a website for travel health professionals and their patients, focusing on the risk and prevention of Japanese encephalitis for travelers to Asia.

Indication and Usage

IXIARO® is a vaccine indicated for the prevention of disease caused by JE virus, approved for use in individuals 2 months of age and older.

Important Safety Information

Severe allergic reaction (e.g., anaphylaxis) after a previous dose of IXIARO®, any other Japanese encephalitis vaccine, or any component of IXIARO®, including protamine sulfate ─ a compound known to cause hypersensitivity reactions in some individuals ─ is a contraindication to administration of IXIARO®. Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO® might be considered.   

Vaccination with IXIARO® may not protect all individuals.  Immunocompromised individuals may have a diminished immune response to IXIARO®. Syncope can occur in association with administration of injectable vaccines, including IXIARO®. Procedures should be in place to prevent injury from falling and manage syncopal reactions.

The most common ( > 10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to < 1 year of age; fever in children 1 to < 12 years of age; pain and tenderness in adolescents 12 to < 18 years of age; and, headache, myalgia, and injection site pain and tenderness in adults.

Healthcare practitioners are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call +1-800-822-7967. Healthcare practitioners are also encouraged to report inadvertent use in pregnant women to Valneva at +1-844-349-4276 (8443-IXIARO).

Please see full Prescribing Information.
CONTACT


Valneva USA, Inc.
4550 Montgomery Ave., Suite 460
Bethesda, MD 20814, USA

Customer Service
+1-833-403-8778

Medical Information
+1-844-349-4276 
+1-301-556-4500

Please update your browser...